Drugs / GSK189254
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00387413 | Oct 2006 → May 2007 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00366080 | Nov 2006 → Jan 2008 | narcolepsy | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK189254 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00366080 ↗ |
| Known as | [11C]GSK-189254 | ChEMBL registry synonym — accepted as the source's own label CHEMBL517140 ↗ |
| Action | Inhibit | “the Histamine H3 antagonist GSK189254” NCT00366080 ↗1“Histamine H3 receptor antagonist” CHEMBL517140 ↗ |
| Modality | Small molecule | — CHEMBL517140 ↗ |
| Route | Oral | “The effects of repeated oral dosing of GSK189254 and duloxetine on secondary hyperalgesia in the EH model will be determined.” NCT00387413 ↗ |
| Target | HRH3 | “Histamine H3 receptor antagonist” CHEMBL517140 ↗ |